Cargando…

Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting

Epigenetic changes contribute to the profound alteration in the transcriptional program associated with the onset and progression of muscle wasting in several pathological conditions. Although HDACs and their inhibitors have been extensively studied in the field of muscular dystrophies, the potentia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nevi, Lorenzo, Pöllänen, Noora, Penna, Fabio, Caretti, Giuseppina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671811/ https://www.ncbi.nlm.nih.gov/pubmed/38003594 http://dx.doi.org/10.3390/ijms242216404

Ejemplares similares

BETs inhibition attenuates oxidative stress and preserves muscle integrity in Duchenne muscular dystrophy
por: Segatto, Marco, et al.
Publicado: (2020)

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins by JQ1 Unravels a Novel Epigenetic Modulation to Control Lipid Homeostasis
por: Tonini, Claudia, et al.
Publicado: (2020)

Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation
por: Cini, Elena, et al.
Publicado: (2018)

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
por: Kling, Matthew J., et al.
Publicado: (2022)

BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma
por: Gusyatiner, Olga, et al.
Publicado: (2021)

SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways
por: Bottino, Cinzia, et al.
Publicado: (2020)

Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
por: Borbely, Gabor, et al.
Publicado: (2015)

Modulating Metabolism to Improve Cancer-Induced Muscle Wasting
por: Penna, Fabio, et al.
Publicado: (2018)

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
por: Heinemann, Anja, et al.
Publicado: (2015)

Exercise and Exercise Mimetics for the Treatment of Musculoskeletal Disorders
por: Cento, Alessia S., et al.
Publicado: (2022)

Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure
por: Evans, Levi W., et al.
Publicado: (2018)

Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma
por: Liu, Xiaohua, et al.
Publicado: (2021)

High-Throughput Screening for CEBPD-Modulating Compounds in THP-1-Derived Reporter Macrophages Identifies Anti-Inflammatory HDAC and BET Inhibitors
por: Ullmann, Tatjana, et al.
Publicado: (2021)

Epigenetic Regulation Shapes the Stem Cells State
por: Caretti, Giuseppina, et al.
Publicado: (2016)

Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting
por: Penna, Fabio, et al.
Publicado: (2015)

Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro‐adipogenic progenitors
por: Consalvi, Silvia, et al.
Publicado: (2022)

Inhibition of Osteoclastogenesis and Inflammatory Bone Resorption by Targeting BET Proteins and Epigenetic Regulation
por: Park-Min, Kyung-Hyun, et al.
Publicado: (2014)

To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?
por: Wang, Xiaoyun, et al.
Publicado: (2019)

Epigenetic modulation with oral histone deacetylase (HDAC) inhibitor as a new treatment option in JIA
por: Vojinovic, J, et al.
Publicado: (2011)

Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies
por: Burmeister, Aaron, et al.
Publicado: (2022)

Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
por: Manzotti, Gloria, et al.
Publicado: (2019)

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases
por: Shanmugam, Geetha, et al.
Publicado: (2021)

Epigenetic therapy: BBC1115, a novel BET inhibitor with broad antitumor activity
por: Cingaram, Pradeep Reddy
Publicado: (2023)

Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition
por: Tang, Yujie, et al.
Publicado: (2014)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

Tackling Skeletal Muscle Cells Epigenome in the Next-Generation Sequencing Era
por: Fittipaldi, Raffaella, et al.
Publicado: (2012)

Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells
por: Cortiguera, María G., et al.
Publicado: (2019)

Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells
por: Tay, Rong En, et al.
Publicado: (2020)

HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases
por: Hull, Elizabeth E., et al.
Publicado: (2016)

Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?
por: Claveria-Cabello, Alex, et al.
Publicado: (2020)

Epigenetic intervention with a BET inhibitor ameliorates acute retinal ganglion cell death in mice
por: Li, Jun, et al.
Publicado: (2017)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
por: Mayr, Christian, et al.
Publicado: (2021)

Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes
por: Nebbioso, Angela, et al.
Publicado: (2009)

Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer
por: Li, Yuxin, et al.
Publicado: (2020)

HDAC Inhibitor-Mediated Epigenetic Regulation of Glaucoma-Associated TGFβ2 in the Trabecular Meshwork
por: Bermudez, Jaclyn Y., et al.
Publicado: (2016)

Correction: Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells
por: Tay, Rong En, et al.
Publicado: (2020)

Epigenetic Modulation with HDAC Inhibitor CG200745 Induces Anti-Proliferation in Non-Small Cell Lung Cancer Cells
por: Chun, Sung-Min, et al.
Publicado: (2015)

Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia
por: Rausch, Valentina, et al.
Publicado: (2021)

BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling
por: Dai, Zhiyu, et al.
Publicado: (2019)

Vitamin D and VDR in cancer cachexia and muscle regeneration
por: Camperi, Andrea, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jk9cuqaihh91ht27tf4sneqadu